Aldeyra Therapeutics Inc

NASDAQ:ALDX   3:59:57 PM EDT
12.16
+0.19 (+1.59%)
Products

Aldeyra Receives Study May Proceed Letter From FDA For Clinical Trial Of Adx-629 In Covid-19 Patients

Published: 09/09/2020 12:17 GMT
Aldeyra Therapeutics Inc (ALDX) - Aldeyra Receives Study May Proceed Letter From FDA to Initiate Clinical Trial of Adx-629 in Covid-19 Patients.
Aldeyra Therapeutics Inc - Planned Phase 2 Clinical Trial is Expected to Enroll Approximately 30 Patients With Covid-19.
Aldeyra Therapeutics - Additional Proof of Concept Phase 2a Clinical Trials of Adx-629 in Psoriasis, Atopic Asthma Expected to Initiate in Q4 2020.